Financials and Estimates

Financials and Estimates

Over the last three years Booz Allen grew revenue from $10.7B to a $12.0B peak and back to $11.2B [1], while free cash flow swung far more than the income statement — from $192M in FY2024 to roughly $950M in each of FY2025 and FY2026 [2]. The reported earnings decline looks mild, but most of what cushioned it does not repeat.

Booz Allen's FY2026 net income fell only 9% while operating income fell 25% — a gap bridged by a tax charge that collapsed from $284M (23.3%) to $11M (1.3%) — and the FY2025 base it is measured against was itself inflated by ~$237M of one-time settlement benefits ($122M reserve release + $115M insurance recovery) while the FY2026 result was defended by a 12% workforce cut (~35,800 to ~31,500) and $61M of severance, so the earnings 'resilience' is largely constructed rather than operational. [3][4][5][6], Notes — Severance and Related Charges — p.135"), Notes — Severance and Related Charges — p.135").

Each leg is sizeable against the −9% headline: a $273M tax swing ($284M to $11M), a FY2025 base lifted roughly $237M by non-recurring settlement items, and $61M of severance behind the headcount cut [7]. On management's own bridge, the run-rate to anchor a multiple on is nearer $5.90 a share than the $6.90 GAAP or $6.51 adjusted figures [8]. The counter is equally concrete: the largest single piece of the low tax rate — the $103M R&D credit — is structural and recurs [9], and FY2027 guidance still lands at $6.00–$6.35 on a normalized 20–23% tax rate, so the clean base is real rather than a one-off [10].

Why net income held up better than operating income

The gap between the −25% operating-income decline and the −9% net-income decline is worth pausing on, because it is where the earnings quality lives. Operating income fell from $1,370M to $1,033M as margin compressed from 11% to 9% [11]. Below the operating line, interest expense rose to $184M and pre-tax income landed at $862M — yet the tax charge collapsed from $284M (a 23.3% rate) to $11M, a 1.3% effective rate [12]. That $273M tax swing is why net income of $851M looks resilient.

The tax note itself separates the recurring from the one-off. Against the 21% federal statutory charge of $181M, research-and-development credits removed $103M (12.0 points) and a favorable change in uncertain tax positions removed a further $80M (9.3 points) [13]. The R&D credit is a repeatable feature of a labor-and-engineering business; the reserve release is not.

Management's own bridge does the subtraction. Its FY2027 earnings bridge starts from the $6.51 adjusted EPS reported for FY2026, removes $0.11 of unrealized venture-investment gains and $0.50 of "non-recurring portion of R&D tax credit benefit," and arrives at a clean base of $5.90 [14]. Two facts follow. First, this is one of the rare cases where GAAP diluted EPS ($6.90) sits above the adjusted figure ($6.51) — the ordering is inverted precisely because GAAP captured the tax benefit that the non-GAAP measure normalizes away [15]. Second, the honest run-rate to anchor a valuation on is nearer $5.90 than $6.90.

The durability of the read turns on the R&D-credit level holding and on whether reserve releases keep recurring; a snap-back to a full statutory rate on the current pre-tax base would cut EPS by roughly a dollar.

The three-year record

Source: FY2026 Annual Report (Form 10-K), Consolidated Statements of Operations and Cash Flows [16] [17].

The revenue line tells a cyclical, not linear, story. Revenue rose 12% in FY2024 and 12% again in FY2025 to $11,980M, then fell 6% to $11,217M in FY2026 as a slowed procurement environment — including the third-quarter government shutdown — cut headcount and billable expenses [18]. Operating margin has been just as variable: 4.8% in FY2023, recovering to a 11.4% peak in FY2025 before settling at 9.2% in FY2026. FY2023 is the useful precedent — a prior margin trough the business worked its way out of within two years.

Source: FY2026 Annual Report (Form 10-K), Consolidated Statements of Operations [19]; FY2022–FY2024 from FY2024 Annual Report (Form 10-K) [20].

Source: derived from reported operating income and revenue, FY2024–FY2026 Annual Reports [21] [22].

Cash economics

Free cash flow is the number this business is usually bought for, and it has been the least stable line of all. Operating cash flow was $259M in FY2024, $1,009M in FY2025, and $1,041M in FY2026; against modest capital spending of $67M, $98M and $90M, free cash flow ran $192M, $911M and $951M [23].

Source: FY2026 Annual Report (Form 10-K), Consolidated Statements of Cash Flows and Operations [24].

Both extremes have identifiable, non-recurring mechanisms. The FY2024 trough was a cash-tax event: the required capitalization of research costs drove large tax payments and a $270M build in receivables, so only 43% of that year's $606M net income converted to operating cash [25]. FY2026 flatters in the opposite direction: as revenue shrank, receivables unwound, releasing $207M of cash and lifting operating cash flow above net income even as the business contracted [26]. Excluding that working-capital tailwind, underlying free cash flow is nearer $750M. Across all three years, cumulative free cash flow of $2.05B against $2.39B of net income is a 86% conversion rate — respectable, but flattered at the front by FY2026 and depressed at the back by FY2024, so no single year is a clean run-rate.

Balance sheet and the bankruptcy question

For a reader who wants the chance of ruin near zero, the debt is serviceable but the equity offers no asset cushion. Net debt was $3,212M at FY2026 — total debt of $3,940M less $728M of cash — against adjusted EBITDA of $1,229M, or about 2.6x [27] [28]. Operating income covers net interest 5.6 times, and total liquidity was $2.2B — $728M of cash plus $1.5B available under the revolver — with the nearest large maturity being the 5.95% notes due 2035 [29]. On coverage and maturity profile, near-term default risk is low.

The asset side is the caution. Reported equity is only $1,105M, and that already sits after $3,673M of treasury stock accumulated through years of buybacks; goodwill ($2,399M) and other intangibles ($509M) together are 41% of the $7,118M balance sheet [30]. Net of those soft assets, tangible book equity is roughly negative $1.8B. This is a cleared-workforce-and-contracts business, not an asset play: the margin of safety, if there is one, has to come from cash flow and backlog coverage, not from anything a liquidator could sell.

Source: FY2026 Annual Report (Form 10-K), Consolidated Balance Sheets; tangible equity derived as reported equity less goodwill and intangibles [31].

Capital returns stayed heavy through the downturn. In FY2026 the company paid $276M of dividends ($2.24 per share, since raised to $0.59 quarterly) and repurchased 5.6 million shares for $561M, with $684M left under the authorization [32]. Combined returns of roughly $837M sat just inside the $951M of free cash flow — sustainable at this level, but with little room to spare if free cash flow reverts toward the underlying $750M.

Forward estimates

Management's FY2027 guidance is for stabilization rather than recovery: revenue of $11.2–$11.7B (0–4% growth), adjusted EBITDA of $1,240–$1,290M at roughly 11% margin, adjusted EPS of $6.00–$6.35, and free cash flow of $825–$925M. The guide explicitly assumes the tax rate normalizes to 20–23% and capital spending steps up to $220M, of which $105M is a new headquarters [33]. Sell-side consensus is close to the midpoint — roughly $11.4B of revenue and $6.29 adjusted EPS for FY2027, building to about $11.9B and $6.85 for FY2028 — with a mean price target near $79 against the current $66, but a rating split that skews cautious: of 13 analysts, two buys, eight holds and three sells (per compiled analyst estimates).

Source: FY2025–FY2026 reported revenue, FY2026 Annual Report (Form 10-K) [34]; FY2027–FY2028 are compiled analyst consensus.

One forward-looking anchor cuts against the falling top line: total backlog rose to $38,187M at FY2026 from $37,027M a year earlier, so contracted future work grew even as recognized revenue fell [35]. Backlog is a coverage signal, not a timing guarantee — funded backlog is only $4,319M of that total, and the rest depends on options being exercised and appropriations flowing — but a building book while revenue troughs is more consistent with a cyclical pause than a structural unwind.

On the current $66 price and about 120 million diluted shares, the market values the equity near $7.9B and the enterprise near $11.1B. That is roughly 10.5x consensus FY2027 adjusted EPS, about 9x enterprise value to FY2027 EBITDA, and an 11% free-cash-flow yield on the guidance midpoint, with a 3.6% dividend yield alongside. Against a clean earnings base of $5.90 the multiple is nearer 11x. Whether that is cheap turns on the durability of the National Security core and the depth of the Civil trough — the operating questions this chapter's financials frame but do not settle.